Zenocutuzumab

• CAT Number: I042139
• CAS Number: 1969309-56-5
• Purity: ≥95%

Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3[1].
Zenocutuzumab (0.001-1000 nM; 96 hours) inhibits cell growth in lung and breast cancer cell lines[1].
Zenocutuzumab (0.1-1000 nM; 24 hours) inhibits HER3 and AKT phosphorylation, induces markers of apoptosis and cell cycle arrest in lung and breast cancer cell lines[1].
Zenocutuzumab (2.5-25 mg/kg; i.p.; once weekly; for 28 days) causes a statistically significant reduction of growth, including tumor regression[1].

Reference

[1]. Alison M Schram, et al. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247.
 [Content Brief]